Publication
Title
Is anti-hormonal treatment in DCIS of the breast a need?
Author
Abstract
Ductal carcinomas in situ (DCIS) represent one fifth of all detected breast cancers. The detection of DCIS can be regarded as collateral damage of breast cancer screening. The treatment of DCIS is based on surgery with or without radiotherapy. Women treated for DCIS have a 10 years survival of 98 %. Could there be a role for systemic therapy in case of a DCIS? Recent published studies suggest there is. However, anti-hormonal therapy (tamoxifen, anastrozole) in DCIS causes an increased morbidity without a reduced mortality. There is an urgent need for evidence-based guidelines in the management of DCIS in order to make appropriate shared decisions.
Language
English
Source (journal)
Facts, views & vision in obgyn : issues in obstetrics, gynaecology and reproductive health. - Place of publication unknown
Publication
Place of publication unknown : Flemish Society of Obstetrics, Gynaecology & Reproductive Health , 2016
ISSN
2032-0418
Volume/pages
8 :3 (2016) , p. 179-181
Pubmed ID
28003873
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identifier
Creation 06.03.2024
Last edited 07.03.2024
To cite this reference